Alkermes Plc
NASDAQ:ALKS

  • LAST PRICE
    24.0550
  • TODAY'S CHANGE (%)
    0.6550 (2.7991%)
  • Bid / Lots
    23.5000/ 9
  • Ask / Lots
    24.4000/ 2
  • Open / Previous Close
    23.6600 / 23.4000
  • Day Range
    23.4400
    24.1700
  • 52 Week Range
    22.0100
    33.7100
  • Volume
    2,008,755

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ALKS
Alkermes Plc
4.0B
6.9x
---
EXEL
Exelixis Inc
6.3B
33.9x
-21.77%
PTCT
PTC Therapeutics Inc
2.8B
-4.9x
---
NVAX
Novavax Inc
2.1B
-5.7x
---
PIII
P3 Health Partners Inc
158.7M
-0.8x
---
HALO
Halozyme Therapeutics Inc
5.6B
18.6x
---
As of 2024-06-03

Company Information

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Contact Information

Headquarters
Connaught House 1 Burlington Road, Dublin 4DUBLIN, Ireland D04 C5Y6
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Richard Pops
Interim Chief Financial Officer, Chief Operating Officer, Executive Vice President, Interim Chief Accounting Officer, Chief Risk Officer
Blair Jackson
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
David Gaffin
Executive Vice President, Research and Development and Chief Medical Officer
Craig Hopkinson
Senior Vice President, Chief Commercial Officer
C.Todd Nichols

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$4.0B
Revenue (TTM)
$1.7B
Shares Outstanding
169.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.45
EPS
$3.50
Book Value
$7.20
P/E Ratio
6.9x
Price/Sales (TTM)
2.3
Price/Cash Flow (TTM)
6.0x
Operating Margin
29.25%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.